Fifth Lane Capital, LP Liquidia Corp Call Options Transaction History

Fifth Lane Capital, LP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$5.77 - $12.19 $192,718 - $407,146	-33,400 Reduced 37.7%	55,200 $664,000
Q3 2023 Nov 14, 2023	BUY	$6.27 - $8.15 $158,004 - $205,380	25,200 Added 39.75%	88,600 $561,000
Q2 2023 Aug 03, 2023	BUY	$6.63 - $9.9 $420,342 - $627,660	63,400 New	63,400 $497,000
Q1 2023 May 15, 2023	BUY	$5.72 - $7.91 $0 - $0	0 New	0 $0

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Fifth Lane Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Fifth Lane Capital, LP with notifications on news.